Swapna Reddy, MD
Dermatology · Elmer
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Schweiger Dermatology PC · Premier Medical Group of the Hudson Valley PC
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Reddy’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A169715 · Delinquent
Licence status: Delinquent · since 2020 · expires 2024-08-31 · Albany Medical College of Union University.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Florida ME152476Medical Doctor · since 2021 · expires 2026-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
4 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Dermatology
Education
- Albany Medical College2005–2009
Residency and fellowship
- University of Rochester Medical Center/Strong Memorial Hosp, DERMATOLOGYRochester, NY · 2015–2018
- Albany Medical Center, INTERNAL MEDICINEAlbany, NY · 2010–2012
- Tuffs Medical Center, RADIOLOGYBoston, MA · 2010–2010
- Boston University Medical Center, INTERNAL MEDICINEBoston, MA · 2009–2010
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- Out of State · NY
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California · Massachusetts · New Jersey · New York · Rhode Island
Original Medicare doctor bills
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Removal of skin lesions | 13 | More than 60% of doctors who do this |
| Skin biopsy | 1-10 | None |
Year by year
| 2023 | 15 | 35 | 73 | 0.86 | $4,377 | $1,724 |
| 2022 | 28 | 92 | 74 | 0.98 | $24,624 | $1,352 |
| 2021 | 242 | 553 | 71 | 1.33 | $125,658 | $31,310 |
| 2020 | 223 | 508 | 70 | 1.29 | $79,564 | $18,771 |
| 2019 | 275 | 727 | 71 | 1.29 | $112,997 | $27,869 |
| 2018 | 174 | 392 | 71 | 1.28 | $68,219 | $19,522 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 1 service
| Short return visit (20+ min) | 13 | $220 | $17 |
2021: 13 services
| Return visit (30+ min) | 65 | $6,663 | $99 |
| Short return visit (20+ min) | 64 | $4,641 | $71 |
| New patient visit (45+ min) | 31 | $4,084 | $132 |
| New patient visit (30+ min) | 30 | $2,517 | $84 |
| Destruction of precancer skin growth, 1 growth | 44 | $2,172 | $48 |
| Biopsy of related skin growth, first growth | 18 | $1,494 | $83 |
| Destruction of skin growth, 1-14 growths | 18 | $1,412 | $78 |
| Return visit (30+ min) | 19 | $914 | $42 |
| New patient visit (30+ min) | 17 | $581 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $529 | $5 |
| Destruction of precancer skin growth, 1 growth | 15 | $357 | $24 |
| Short return visit (20+ min) | 11 | $314 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 13 | $15 | $1 |
2020: 10 services
| Return visit (30+ min) | 75 | $5,046 | $49 |
| Short return visit (20+ min) | 82 | $3,499 | $35 |
| Destruction of precancer skin growth, 1 growth | 56 | $2,066 | $33 |
| New patient visit (45+ min) | 23 | $1,582 | $69 |
| New patient visit (30+ min) | 37 | $1,481 | $40 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $994 | $62 |
| Biopsy of related skin growth, first growth | 29 | $697 | $23 |
| Short return visit | 25 | $475 | $18 |
| New patient visit (15+ min) | 14 | $363 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 35 | $57 | $2 |
2019: 13 services
| Return visit (30+ min) | 65 | $5,109 | $53 |
| Short return visit (20+ min) | 97 | $4,767 | $35 |
| New patient visit (30+ min) | 105 | $4,723 | $45 |
| Destruction of precancer skin growth, 1 growth | 79 | $3,568 | $35 |
| New patient visit (45+ min) | 36 | $2,711 | $75 |
| Biopsy of related skin growth, first growth | 44 | $1,357 | $29 |
| Destruction of skin growth, 1-14 growths | 27 | $1,265 | $45 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $995 | $71 |
| New patient visit (15+ min) | 27 | $869 | $32 |
| Short return visit | 34 | $588 | $17 |
| Injection into skin growth, 1-7 growths | 11 | $351 | $23 |
| Biopsy of related skin growth, each additional growth | 14 | $320 | $18 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $77 | $2 |
2018: 8 services
| New patient visit (30+ min) | 125 | $7,276 | $58 |
| New patient visit (45+ min) | 41 | $3,970 | $97 |
| Destruction of precancer skin growth, 1 growth | 47 | $1,906 | $39 |
| Short return visit (20+ min) | 30 | $1,305 | $40 |
| Destruction of skin growth, 1-14 growths | 21 | $1,108 | $50 |
| Return visit (30+ min) | 11 | $934 | $58 |
| Biopsy of single growth of skin and/or tissue | 22 | $738 | $31 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $68 | $2 |
Medicaid work
$9,101 in 2024
Medicaid paid $9,101 for 199 billed services this clinician did in 2024, up to 51 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 51 | $3,164 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 14 | $1,347 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 26 | $1,257 |
| Short return visit (20+ min) | 45 | $1,115 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 12 | $1,016 |
| Return visit (30+ min) | 25 | $883 |
| Injection, intralesional; up to and including 7 lesions | 13 | $276 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $42 |
| 2024 | 199 | 8 | 51 | $9,101 |
| 2023 | 24 | 1 | 24 | $1,460 |
| 2021 | 119 | 3 | 27 | $9,108 |
| 2020 | 27 | 2 | 14 | $868 |
| 2019 | 38 | 3 | 13 | $860 |
| 2018 | 133 | 1 | 18 | $5,874 |
See the largest Medicaid services in earlier years
2023
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 24 | $1,460 |
2021
| New patient visit (30+ min) | 58 | $4,431 |
| New patient visit (45+ min) | 43 | $3,911 |
| Return visit (30+ min) | 18 | $766 |
2020
| Hospital outpatient clinic visit for assessment and management of a patient | 14 | $481 |
| Short return visit (20+ min) | 13 | $387 |
2019
| New patient visit (30+ min) | 12 | $404 |
| Short return visit (20+ min) | 13 | $280 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $176 |
2018
| New patient visit (30+ min) | 133 | $5,874 |
Drugs they prescribed that Part D paid
$60,059
Pharmacies billed $60,059 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 297) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
281 generic and 16 brand-name prescriptions · $60,059 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 44 | $2,599 | $35 |
| Metronidazole | 15 | $1,011 | $51 |
| Triamcinolone Acetonide | 52 | $890 | $13 |
| Fluorouracil | 13 | $794 | $57 |
| Ketoconazole | 15 | $222 | $12 |
See all 6 drugs
| Clobetasol Propionate | 44 | $2,599 | $35 |
| Metronidazole | 15 | $1,011 | $51 |
| Triamcinolone Acetonide | 52 | $890 | $13 |
| Fluorouracil | 13 | $794 | $57 |
| Ketoconazole | 15 | $222 | $12 |
| Hydrocortisone | 26 | $215 | $6 |
Year by year
| 2024 | 297 | 150 | 0% (0) | 5% | $60,059 |
| 2023 | 107 | 62 | 0% (0) | None | $14,667 |
| 2022 | 123 | 54 | 0% (0) | 21% | $137,544 |
| 2021 | 777 | 228 | 0% (0) | 14% | $571,913 |
| 2020 | 880 | 198 | 0% (0) | 16% | $658,850 |
| 2019 | 875 | 232 | 0% (0) | 17% | $604,605 |
| 2018 | 541 | 185 | 0% (0) | 18% | $161,101 |
| 2017 | 558 | 195 | 0% (0) | 12% | $243,582 |
| 2016 | 611 | 215 | 0% (0) | 18% | $194,748 |
| 2015 | 520 | 209 | 0% (0) | None | $330,711 |
| 2014 | 166 | 23 | None | None | $10,706 |
| 2013 | 50 | 15 | None | None | $3,611 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Clobetasol Propionate | 19 | $2,060 | $108 |
| Triamcinolone Acetonide | 28 | $432 | $15 |
| Hydrocortisone | 17 | $109 | $6 |
2022: 4 drugs
| Clobetasol Propionate | 17 | $1,780 | $105 |
| Triamcinolone Acetonide | 21 | $460 | $22 |
| Ketoconazole | 11 | $180 | $16 |
| Hydroxyzine | 11 | $92 | $8 |
2021: 20 drugs
| Humira(Cf) | 22 | $182,272 | $8,285 |
| Bexarotene | 11 | $115,636 | $10,512 |
| Cosentyx Pen (2 Pens) | 11 | $85,027 | $7,730 |
| Clobetasol Propionate | 88 | $7,180 | $82 |
| Halobetasol Propionate | 61 | $6,632 | $109 |
| Tacrolimus | 19 | $4,137 | $218 |
| Calcipotriene | 19 | $3,663 | $193 |
| Triamcinolone Acetonide | 139 | $2,791 | $20 |
| Dapsone | 16 | $1,759 | $110 |
| Betamethasone Diprop Augmented | 16 | $1,179 | $74 |
| Clindamycin Phosphate | 19 | $1,164 | $61 |
| Imiquimod | 13 | $1,082 | $83 |
| Fluorouracil | 11 | $1,033 | $94 |
| Fluocinonide | 14 | $975 | $70 |
| Metronidazole | 13 | $970 | $75 |
| Ketoconazole | 59 | $864 | $15 |
| Hydroxyzine | 57 | $785 | $14 |
| Doxycycline Hyclate | 16 | $539 | $34 |
| Gabapentin | 17 | $293 | $17 |
| Hydrocortisone | 25 | $171 | $7 |
2020: 25 drugs
| Humira(Cf) | 19 | $156,015 | $8,211 |
| Cosentyx Pen (2 Pens) | 18 | $149,752 | $8,320 |
| Bexarotene | 11 | $144,997 | $13,182 |
| Tacrolimus | 37 | $8,457 | $229 |
| Halobetasol Propionate | 70 | $7,247 | $104 |
| Clobetasol Propionate | 60 | $5,779 | $96 |
| Calcipotriene | 23 | $3,939 | $171 |
| Triamcinolone Acetonide | 139 | $2,766 | $20 |
| Metronidazole | 20 | $1,960 | $98 |
| Clindamycin Phosphate | 25 | $1,718 | $69 |
| Hydroxyzine | 69 | $1,557 | $23 |
| Betamethasone Dipropionate | 26 | $1,535 | $59 |
| Fluorouracil | 11 | $1,457 | $132 |
| Fluocinonide | 20 | $1,365 | $68 |
| Fluocinolone Acetonide | 11 | $923 | $84 |
| Ketoconazole | 49 | $886 | $18 |
| Doxycycline Hyclate | 24 | $603 | $25 |
| Gentamicin Sulfate | 11 | $594 | $54 |
| Clotrimazole | 12 | $305 | $25 |
| Betamethasone Diprop Augmented | 12 | $293 | $24 |
| Gabapentin | 22 | $239 | $11 |
| Mupirocin | 18 | $193 | $11 |
| Prednisone | 12 | $131 | $11 |
| Hydrocortisone | 24 | $129 | $5 |
| Omeprazole | 12 | $68 | $6 |
2019: 25 drugs
| Bexarotene | 13 | $154,379 | $11,875 |
| Cosentyx Pen (2 Pens) | 11 | $117,100 | $10,645 |
| Mycophenolate Mofetil | 20 | $17,185 | $859 |
| Tacrolimus | 36 | $9,649 | $268 |
| Calcipotriene | 39 | $8,048 | $206 |
| Clobetasol Propionate | 47 | $5,401 | $115 |
| Halobetasol Propionate | 43 | $3,862 | $90 |
| Imiquimod | 22 | $3,592 | $163 |
| Fluocinonide | 46 | $3,384 | $74 |
| Clindamycin Phosphate | 37 | $2,470 | $67 |
| Triamcinolone Acetonide | 138 | $2,231 | $16 |
| Metronidazole | 22 | $1,936 | $88 |
| Fluorouracil | 16 | $1,412 | $88 |
| Doxycycline Hyclate | 37 | $1,338 | $36 |
| Fluocinolone Acetonide | 11 | $938 | $85 |
| Betamethasone Dipropionate | 11 | $716 | $65 |
| Ketoconazole | 41 | $699 | $17 |
| Hydroxyzine | 35 | $578 | $17 |
| Clotrimazole | 24 | $576 | $24 |
| Hydrocortisone | 53 | $564 | $11 |
| Betamethasone Diprop Augmented | 14 | $373 | $27 |
| Levothyroxine | 11 | $154 | $14 |
| Prednisone | 17 | $134 | $8 |
| Mupirocin | 11 | $111 | $10 |
| Spironolactone | 12 | $107 | $9 |
2018: 17 drugs
| Clobetasol Propionate | 40 | $7,595 | $190 |
| Tacrolimus | 18 | $5,855 | $325 |
| Fluocinonide | 32 | $5,854 | $183 |
| Calcipotriene | 27 | $5,742 | $213 |
| Calcipotriene-Betamethasone Dp | 11 | $4,814 | $438 |
| Triamcinolone Acetonide | 95 | $1,755 | $18 |
| Metronidazole | 14 | $1,425 | $102 |
| Clindamycin Phosphate | 14 | $1,060 | $76 |
| Doxycycline Hyclate | 25 | $945 | $38 |
| Betamethasone Diprop Augmented | 14 | $915 | $65 |
| Ketoconazole | 30 | $586 | $20 |
| Mycophenolate Mofetil | 11 | $541 | $49 |
| Hydrocortisone | 35 | $474 | $14 |
| Clotrimazole | 13 | $430 | $33 |
| Mupirocin | 15 | $222 | $15 |
| Prednisone | 11 | $164 | $15 |
| Hydroxyzine | 18 | $147 | $8 |
2017: 18 drugs
| Humira | 15 | $71,358 | $4,757 |
| Calcipotriene | 13 | $5,550 | $427 |
| Clobetasol Propionate | 37 | $4,304 | $116 |
| Tacrolimus | 14 | $3,126 | $223 |
| Clindamycin Phosphate | 19 | $2,706 | $142 |
| Hydroxychloroquine Sulfate | 11 | $2,371 | $216 |
| Fluocinolone Acetonide Oil | 14 | $2,329 | $166 |
| Minocycline | 17 | $2,219 | $131 |
| Doxycycline Hyclate | 24 | $1,604 | $67 |
| Methotrexate | 23 | $1,279 | $56 |
| Fluocinonide | 18 | $1,154 | $64 |
| Ketoconazole | 25 | $1,083 | $43 |
| Triamcinolone Acetonide | 62 | $981 | $16 |
| Ammonium Lactate | 12 | $739 | $62 |
| Hydrocortisone | 29 | $589 | $20 |
| Mycophenolate Mofetil | 13 | $504 | $39 |
| Hydroxyzine | 20 | $331 | $17 |
| Gabapentin | 19 | $240 | $13 |
2016: 14 drugs
| Clobetasol Propionate | 47 | $8,937 | $190 |
| Tacrolimus | 12 | $3,195 | $266 |
| Minocycline | 15 | $2,335 | $156 |
| Clindamycin Phosphate | 24 | $1,780 | $74 |
| Fluocinonide | 23 | $1,584 | $69 |
| Doxycycline Hyclate | 29 | $1,451 | $50 |
| Methotrexate | 47 | $1,404 | $30 |
| Triamcinolone Acetonide | 75 | $1,394 | $19 |
| Mycophenolate Mofetil | 12 | $938 | $78 |
| Ketoconazole | 30 | $903 | $30 |
| Hydrocortisone | 27 | $592 | $22 |
| Hydroxyzine | 15 | $571 | $38 |
| Gabapentin | 30 | $370 | $12 |
| Prednisone | 17 | $114 | $7 |
2015: 13 drugs
| Clobetasol Propionate | 57 | $17,310 | $304 |
| Fluorouracil | 18 | $13,781 | $766 |
| Clindamycin Phosphate | 22 | $3,029 | $138 |
| Doxycycline Hyclate | 15 | $1,851 | $123 |
| Methotrexate | 22 | $1,710 | $78 |
| Mycophenolate Mofetil | 17 | $1,286 | $76 |
| Triamcinolone Acetonide | 57 | $1,140 | $20 |
| Ketoconazole | 23 | $919 | $40 |
| Minocycline | 11 | $502 | $46 |
| Hydroxyzine | 18 | $358 | $20 |
| Gabapentin | 17 | $290 | $17 |
| Hydrocortisone | 13 | $155 | $12 |
| Omeprazole | 11 | $101 | $9 |
2014: 1 drug
| Simvastatin | 19 | $163 | $9 |
Money from drug and device companies
$203 in 2025
| 2025 | 6 | 11 | None | $203 |
| 2024 | 9 | 20 | $2,075 | $2,529 |
| 2023 | 5 | 32 | $15,100 | $18,552 |
| 2022 | 4 | 10 | $3,525 | $3,835 |
| 2021 | 12 | 67 | $15,720 | $19,189 |
| 2020 | 8 | 47 | $28,000 | $29,985 |
| 2019 | 12 | 91 | $23,600 | $27,260 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Rhapsido | $51 | 2 payments
|
| Abbvie | Skyrizi | $50 | 3 payments
|
| Ucb | Bimzelx | $38 | 2 payments
|
| Arcutis Biotherapeutics | Zoryve | $30 | 2 payments
|
| Sun Pharmaceutical Industries | Blu-U | $18 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Cabtreo | $16 | 1 payment
|
See all 11 published payments
| Sun Pharmaceutical Industries | Meals · 2025-11-05 | Blu-U | $18 |
| Novartis Pharmaceuticals | Meals · 2025-10-30 | Cosentyx | $17 |
| Novartis Pharmaceuticals | Meals · 2025-10-28 | Rhapsido | $34 |
| Ucb | Meals · 2025-10-22 | Bimzelx | $20 |
| Ucb | Meals · 2025-10-21 | Bimzelx | $18 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-03-06 | Cabtreo | $16 |
| Arcutis Biotherapeutics | Meals · 2025-02-12 | Zoryve | $15 |
| Abbvie | Meals · 2025-01-28 | Skyrizi | $14 |
| Abbvie | Meals · 2025-01-20 | Rinvoq | $19 |
| Abbvie | Meals · 2025-01-15 | Skyrizi | $18 |
| Arcutis Biotherapeutics | Meals · 2025-01-08 | Zoryve | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,529
| Sun Pharmaceutical Industries | Ilumya | $2,075 | 1 payment
|
| Janssen Biotech | Tremfya | $291 | 10 payments
|
| Abbvie | Skyrizi | $53 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $24 | 1 payment
|
| Dermavant Sciences | Vtama | $22 | 1 payment
|
| Galderma Laboratories L.P. | None | $21 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $15 | 1 payment
|
| Amgen | Otezla | $14 | 1 payment
|
| Incyte | Opzelura | $13 | 1 payment
|
2023: $18,552
| Sun Pharmaceutical Industries | Ilumya | $18,460 | 27 payments
|
| Janssen Biotech | Tremfya | $45 | 2 payments
|
| Journey Medical | None | $18 | 1 payment
|
| Arcutis Biotherapeutics | None | $15 | 1 payment
|
| Incyte | Opzelura | $14 | 1 payment
|
2022: $3,835
| Novartis Pharmaceuticals | Cosentyx | $2,050 | 5 payments
|
| Sun Pharmaceutical Industries | Ilumya | $1,640 | 2 payments
|
| Ucb | Cimzia | $131 | 2 payments
|
| Lilly USA | Taltz | $15 | 1 payment
|
2021: $19,189
| Sun Pharmaceutical Industries | Ilumya | $16,177 | 20 payments
|
| Novartis Pharmaceuticals | Cosentyx | $2,115 | 14 payments
|
| AbbVie | Skyrizi | $320 | 16 payments
|
| Janssen Biotech | Tremfya | $153 | 3 payments
|
| Genzyme | Dupixent | $84 | 4 payments
|
| Pfizer | Eucrisa | $68 | 3 payments
|
| Ucb | Cimzia | $58 | 2 payments
|
| Galderma Laboratories L.P. | Aklief | $53 | 1 payment
|
| Incyte | Opzelura | $52 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Arazlo | $48 | 1 payment
|
| Lilly USA | Taltz | $31 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $31 | 1 payment
|
2020: $29,985
| Sun Pharmaceutical Industries | Ilumya | $29,509 | 23 payments
|
| Janssen Biotech | Tremfya | $159 | 8 payments
|
| AbbVie | Skyrizi | $143 | 8 payments
|
| Novartis Pharmaceuticals | Cosentyx | $51 | 2 payments
|
| Lilly USA | Taltz | $43 | 2 payments
|
| Genzyme | Dupixent | $42 | 2 payments
|
| PruGen Inc. Pharmaceuticals | None | $20 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $18 | 1 payment
|
2019: $27,260
| Sun Pharmaceutical Industries | Ilumya | $25,522 | 19 payments
|
| Novartis Pharmaceuticals | Cosentyx | $555 | 28 payments
|
| AbbVie | Skyrizi | $311 | 11 payments
|
| Galderma Laboratories L.P. | None | $242 | 2 payments
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $142 | 3 payments
|
| Pfizer | Eucrisa | $114 | 12 payments
|
| Janssen Biotech | Tremfya | $111 | 8 payments
|
| Solta Medical a division of Bausch Health US | None | $109 | 1 payment
|
| Endo Pharmaceuticals | None | $68 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $47 | 3 payments
|
| PruGen Inc. Pharmaceuticals | None | $21 | 2 payments
|
| Celgene | Otezla | $18 | 1 payment
|
Professional record
- NPI
- 1467754200
- Licence
- CA A169715, FL ME152476, NY 267493California A169715: Delinquent · expires 2024-08-31Florida ME152476: Active
- Trained
- Albany Medical College of Union University, 2009
- Group
- Schweiger Dermatology PC · Premier Medical Group of the Hudson Valley PC
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Internal medicine (207R00000X)
- Mailing address
- Po Box 100279, Gainesville, FL, 32610
- NPI first listed
- 2010-11-30
- NPI last updated
- 2025-03-27
- NPI record certified
- 2025-03-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1600 Sw Archer Rd, Gainesville, FL, 32610 · 1101 Nott St, Schenectady, NY, 12308 · 1201 Nott St Ste 103, Schenectady, NY, 12308